GlassScriptPhysician profile
Salvador E Peron
NPI 1881691640
$14,125.62
in general payments reported to CMS, 2019-2025
46 companies · $1,780 in 2025
The $1,780 reported for 2025 was more than what 77% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,452 · 2020: $600 · 2021: $2,564 · 2022: $2,605 · 2023: $965 · 2024: $3,160 · 2025: $1,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,617 · Travel and Lodging: $2,205 · Education: $82.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.86 |
| Travel and Lodging | $2,205.11 |
| Education | $82.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $4,175.29 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $1,740.72 | 2019-2024 | |
| Axonics, INC. | $1,713.84 | 2020-2024 | Axonics |
| Astellas Pharma US INC | $1,089.01 | 2019-2025 | Xtandi, Myrbetriq |
| Medtronic, INC. | $1,045.15 | 2021-2025 | Interstim |
| Janssen Biotech, INC. | $613.43 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Olympus America INC. | $508.16 | 2022-2025 | Itind System |
| Pfizer INC. | $281.08 | 2019-2025 | |
| Myovant Sciences INC. | $234.57 | 2021-2022 | |
| Blue Earth Diagnostics | $225.82 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $223.06 | 2019-2023 | Xiaflex |
| Sumitomo Pharma America, INC. | $217.60 | 2023-2025 | Orgovyx |
| Abbvie INC. | $180.70 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $174.76 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $151.88 | 2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $127.28 | 2021 | |
| Procept Biorobotics Corporation | $124.84 | 2022-2025 | Aquabeam System |
| Agiliti Surgical, INC. | $122.65 | 2019-2023 | Sonablate, Trinity |
| Tolmar Pharmaceuticals, INC. | $108.31 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.94 | 2022-2023 | Glassia |
| Baxter Healthcare | $105.94 | 2023-2024 | Perclot, Hillrom - Life 2000 Ventilation System |
| Endo USA, INC. | $94.45 | 2024-2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $90.52 | 2023-2025 | Endosheath Technology |
| Clovis Oncology, INC. | $63.02 | 2020-2021 | |
| Smith+Nephew, INC. | $62.09 | 2023-2024 | Stravix |
| Ferring Pharmaceuticals INC. | $59.82 | 2019 | |
| Tolmar, INC. | $51.65 | 2023-2025 | Eligard, Jatenzo |
| Urogen Pharma, INC. | $51.35 | 2023-2025 | Jelmyto |
| Neotract INC. | $42.76 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.20 | 2023-2024 | |
| Ambu INC. | $30.45 | 2024 | |
| 180 Medical, INC. | $30.00 | 2024 | Self-Cath |
| Allergan, INC. | $27.16 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $20.95 | 2020 | |
| Glaxosmithkline, LLC. | $20.61 | 2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.13 | 2023 | Ofev |
| Richard Wolf Medical Instruments Corp. | $19.61 | 2019 | |
| Caldera Medical, INC | $18.89 | 2023 | Desara |
| Medtronic USA, INC. | $18.74 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $18.11 | 2024 | Lumryz |
| Cook Medical LLC | $17.74 | 2023 | Resonance |
| Heron Therapeutics, INC. | $17.00 | 2025 | Zynrelef |
| Hollister Incorporated | $15.24 | 2021 | |
| Coloplast Corp | $12.50 | 2019 | |
| Srs Medical Systems, INC. | $11.60 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$868.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvador Peron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.